October 13, 2017 08:43 AM EDT

Lupin is prepping a $1B US deal spree; Protagonist raising $60M for trial work

Shehla Shakoor

Managing Director

→ Coming off of a $150 million deal to buy Symbiomix, Mumbai-based Lupin says it’s planning a $1 billion deal spree aimed at building a women’s health group in the US.

→ Protagonist Therapeutics $PTGX is raising $60 million through a private offering. The money will be earmarked for its clinical work on three drug candidates: PTG-100, PTG-200, and PTG-300.

→ AstraZeneca spinoff Entasis has bagged its second CARB-X award for its work on new antibiotics. The Waltham, MA-based biotech gets $3.8 million initially plus a shot at another $6.3 million.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Lupin is prepping a $1B US deal spree; Protagonist raising $60M for trial work

Shehla Shakoor

Managing Director

Unlock this article instantly by becoming a free subscriber.

AbbVie makes second deal in a week, betting $8.7B in cash on CNS biotech Cerevel

Pfizer plans to pull out of BIO, following moves by other large drugmakers to reduce lobbying footprint

Aviv Regev leads Genentech's next revolution with AI

FDA approves Novartis drug for rare blood disorder

FDA sends letter to Novartis over Kymriah manufacturing safety concerns

Early prediction of outcomes in DLBCL clinical trials through MRD testing

Lupin is prep­ping a $1B US deal spree; Pro­tag­o­nist rais­ing $60M for tri­al work

Shehla Shakoor

Managing Director

Unlock this article instantly by becoming a free subscriber.

Ab­b­Vie makes sec­ond deal in a week, bet­ting $8.7B in cash on CNS biotech Cerev­el

Pfiz­er plans to pull out of BIO, fol­low­ing moves by oth­er large drug­mak­ers to re­duce lob­by­ing foot­print

Aviv Regev leads Genen­tech's next rev­o­lu­tion with AI

FDA ap­proves No­var­tis drug for rare blood dis­or­der

FDA sends let­ter to No­var­tis over Kym­ri­ah man­u­fac­tur­ing safe­ty con­cerns

Ear­ly pre­dic­tion of out­comes in DL­B­CL clin­i­cal tri­als through MRD test­ing

Lupin is prepping a $1B US deal spree; Protagonist raising $60M for trial work

AbbVie makes second deal in a week, betting $8.7B in cash on CNS biotech Cerevel

Pfizer plans to pull out of BIO, following moves by other large drugmakers to reduce lobbying footprint

Aviv Regev leads Genentech's next revolution with AI

FDA approves Novartis drug for rare blood disorder

FDA sends letter to Novartis over Kymriah manufacturing safety concerns

Early prediction of outcomes in DLBCL clinical trials through MRD testing